BRL-52537

BRL-52537
(IUPAC) ime
	2-(3,4-diclorofenil)-1-[(2S)-2-(pirolidin-1-ilmetil)piperidin-1-il]etanon
Klinički podaci
Identifikatori
CAS broj	130497-33-5
ATC kod	nije dodeljen
PubChem	6603740
Hemijski podaci
Formula	C18H24Cl2N2O
Mol. masa	355.301 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C18H24Cl2N2O/c19-16-7-6-14(11-17(16)20)12-18(23)22-10-2-1-5-15(22)13-21-8-3-4-9-21/h6-7,11,15H,1-5,8-10,12-13H2/t15-/m0/s1 ; Key: GHCCBWMZKJQGLS-HNNXBMFYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

BRL-52537 je lek koji deluje kao potentan i visoko selektivan κ-opioidni agonist.^[3] On je pokazao neuroprotektivno dejstvo u studijama na životinjama,^[4]^[5] i koristi se za istraživanje potencijalnih tretmana za moždani i srčani udar, kao i za neka uopštenija istraživanja mozga.^[6]^[7]^[8]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Vecchietti V, Giordani A, Giardina G, Colle R, Clarke GD (January 1991). „(2S)-1-(arylacetyl)-2-(aminomethyl)piperidine derivatives: novel, highly selective kappa opioid analgesics”. Journal of Medicinal Chemistry 34 (1): 397–403. PMID 1846921.
↑ Goyagi T, Toung TJ, Kirsch JR, Traystman RJ, Koehler RC, Hurn PD, Bhardwaj A (June 2003). „Neuroprotective kappa-opioid receptor agonist BRL 52537 attenuates ischemia-evoked nitric oxide production in vivo in rats”. Stroke; a Journal of Cerebral Circulation 34 (6): 1533–8. DOI:10.1161/01.STR.0000072512.30658.E7. PMID 12738895.
↑ Zhang Z, Chen TY, Kirsch JR, Toung TJ, Traystman RJ, Koehler RC, Hurn PD, Bhardwaj A (December 2003). „Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats”. Anesthesia and Analgesia 97 (6): 1776–83. PMID 14633559.
↑ Chen TY, Goyagi T, Toung TJ, Kirsch JR, Hurn PD, Koehler RC, Bhardwaj A (May 2004). „Prolonged opportunity for ischemic neuroprotection with selective kappa-opioid receptor agonist in rats”. Stroke; a Journal of Cerebral Circulation 35 (5): 1180–5. DOI:10.1161/01.STR.0000125011.93188.c6. PMID 15031456.
↑ Peart JN, Gross ER, Gross GJ (March 2004). „Effect of exogenous kappa-opioid receptor activation in rat model of myocardial infarction”. Journal of Cardiovascular Pharmacology 43 (3): 410–5. PMID 15076225.
↑ Britt JP, McGehee DS (February 2008). „Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in the nucleus accumbens”. The Journal of Neuroscience : the Official Journal of the Society for Neuroscience 28 (7): 1672–81. DOI:10.1523/JNEUROSCI.4275-07.2008. PMID 18272687.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[pmid1846921-3] Vecchietti V, Giordani A, Giardina G, Colle R, Clarke GD (January 1991). „(2S)-1-(arylacetyl)-2-(aminomethyl)piperidine derivatives: novel, highly selective kappa opioid analgesics”. Journal of Medicinal Chemistry 34 (1): 397–403. PMID 1846921.

[pmid12738895-4] Goyagi T, Toung TJ, Kirsch JR, Traystman RJ, Koehler RC, Hurn PD, Bhardwaj A (June 2003). „Neuroprotective kappa-opioid receptor agonist BRL 52537 attenuates ischemia-evoked nitric oxide production in vivo in rats”. Stroke; a Journal of Cerebral Circulation 34 (6): 1533–8. DOI:10.1161/01.STR.0000072512.30658.E7. PMID 12738895.

[pmid14633559-5] Zhang Z, Chen TY, Kirsch JR, Toung TJ, Traystman RJ, Koehler RC, Hurn PD, Bhardwaj A (December 2003). „Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats”. Anesthesia and Analgesia 97 (6): 1776–83. PMID 14633559.

[pmid15031456-6] Chen TY, Goyagi T, Toung TJ, Kirsch JR, Hurn PD, Koehler RC, Bhardwaj A (May 2004). „Prolonged opportunity for ischemic neuroprotection with selective kappa-opioid receptor agonist in rats”. Stroke; a Journal of Cerebral Circulation 35 (5): 1180–5. DOI:10.1161/01.STR.0000125011.93188.c6. PMID 15031456.

[pmid15076225-7] Peart JN, Gross ER, Gross GJ (March 2004). „Effect of exogenous kappa-opioid receptor activation in rat model of myocardial infarction”. Journal of Cardiovascular Pharmacology 43 (3): 410–5. PMID 15076225.

[pmid18272687-8] Britt JP, McGehee DS (February 2008). „Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in the nucleus accumbens”. The Journal of Neuroscience : the Official Journal of the Society for Neuroscience 28 (7): 1672–81. DOI:10.1523/JNEUROSCI.4275-07.2008. PMID 18272687.

[1]